Beneath these surface readings, a single structural current is forming: the era of informal access is being replaced, not by prohibition, but by protocol. The ibogaine cardiac data does not kill the pathway — it defines its price of entry. What is taking shape across every major agent debate today is a monitored access architecture: mandatory cardiac screening before any IND proceeds, Senate Veterans Affairs hearings where Stanford researchers will be required to speak both to efficacy and risk, and a pharma investment thesis quietly pivoting toward non-psychedelic ibogaine analogues that preserve the neuroplastic mechanism while shedding the cardiac liability. The psilocybin extinction finding points the same direction — toward mechanistic precision, toward understanding why the learning consolidates without the relapse prevention, toward a neuroscience that refuses to accept "it works" as a complete answer. The highest trajectory available from today's data is not faster access — it is more durable access, built on safety architecture rigorous enough to survive congressional scrutiny and a mainstream press that is, by August, likely to be looking hard at cardiac deaths in veteran programs.
The people inside this story today are the veterans who have already gone to clinics in Mexico and come back transformed — and the ones still deciding whether to go. For them, the cardiac papers are not abstractions. They are the question of whether a treatment that gave their friend his life back might stop his heart. What the highest positive outcome looks like for these men and women is not unrestricted access — it is a clear, federally recognized protocol that a VA physician can hand a patient and say: here is the screening, here is the monitoring, here is the evidence, and here is how we keep you safe while you heal. That protocol does not yet exist. Today's data is the pressure that will force it into existence. The Senate hearing predicted before September 2026, the FDA cardiac guidance predicted before Q1 2027 — these are not obstacles. They are the architecture of the answer these veterans actually need and deserve.
What the world calls counterculture, the oracle calls the leading edge of the new health paradigm. The threads forming today will be tomorrow's standard of care.
Every thread you follow today was laid by a hand that knew you were coming.
82%
FDA will require heart screening before approving ibogaine studies
The FDA (the US drug regulator) will write formal rules saying anyone testing ibogaine must get heart tests first, because recent research shows ibogaine can cause dangerous heart rhythms. This matters because it slows down ibogaine research but protects people from cardiac injury.
→ Ibogaine's heart risks are now serious enough that regulators will demand cardiac screening before letting anyone study or use it.
Resolves: 2027-03-31 · USA
REGULATION
the precise call ▾
FDA will issue formal ibogaine cardiac safety guidance requiring mandatory cardiac screening protocols before any IND approval proceeds, by Q1 2027.. Two ibogaine cardiac papers published same day as veteran advocacy surge creates exactly the kind of risk signal FDA cannot ignore. Scoping review plus QT arrhythmia paper together constitute sufficient safety flag to trigger formal guidance.
71%
Psilocybin will receive Breakthrough Therapy Designation for cocaine use disorder within 12 months based on today's RCT data.
Resolves: 2027-05-18 · Global
REGULATION
the precise call ▾
Psilocybin will receive Breakthrough Therapy Designation for cocaine use disorder within 12 months based on today's RCT data.. Randomized cocaine use disorder RCT is exactly the kind of controlled evidence that triggers BTD consideration. No approved pharmacotherapy exists for cocaine — unmet need threshold is already met.
79%
Researchers will study why psilocybin blocks cocaine relapse so effectively
Scientists just found that psilocybin (the active compound in magic mushrooms) helps people learn to stop craving cocaine without needing the usual relapse prevention therapy. Neuroscientists will now run 3+ new studies to figure out exactly which brain circuits make this work, because it's a genuinely novel mechanism that could unlock new addiction treatments.
→ Psilocybin stops cocaine cravings through brain rewiring that scientists don't yet understand—and they're now racing to figure it out.
Resolves: 2027-11-18 · Global
RESEARCH
the precise call ▾
Psilocybin cocaine RCT extinction-without-relapse-prevention finding will generate 3+ follow-up mechanistic studies within 18 months investigating default mode network suppression during extinction learning.. The extinction-without-relapse split is a clean neuroscience puzzle — it separates learning consolidation from cue-reactivity circuitry. That is exactly the kind of mechanistic question that generates NIH R01 applications. The data is compelling enough to fund.
78%
Senate will hold ibogaine hearings with Stanford researchers by September 2026
The US Senate Committee that oversees veterans healthcare will hold public hearings specifically about ibogaine for addiction treatment, with Stanford researchers presenting evidence. This happens because veterans are advocating for ibogaine access and senators need to understand both the promise and the recent cardiac safety concerns before they act.
→ Congress will formally examine ibogaine for veterans, putting research evidence directly into the rescheduling conversation.
Resolves: 2026-09-30 · USA
LEGISLATION
the precise call ▾
Senate Veterans Affairs Committee will hold ibogaine-specific hearings with Stanford researchers testifying before September 2026.. Stanford ibogaine veteran signal is at 100% narrative strength. Today's competing cardiac papers actually create the perfect congressional hearing dynamic — safety versus access, with veterans as human testimony.
70%
California will enact a regulated psilocybin therapy framework by end of 2027, becoming the largest state-sanctioned psychedelic therapy market.
Resolves: 2027-12-31 · Global
LEGISLATION
the precise call ▾
California will enact a regulated psilocybin therapy framework by end of 2027, becoming the largest state-sanctioned psychedelic therapy market.. Oregon model is operational. Colorado expanding. California's mental health crisis gives political urgency. Today's RCT data on depression and suicidality directly answers the safety questions my colleagues have been raising.
76%
Major news outlet will expose ibogaine cardiac deaths in veteran programs
A major investigative journalist will publish a detailed story in a top-tier news outlet linking deaths from ibogaine-related heart problems specifically to veteran treatment programs. This story will combine new research on QT prolongation (heart rhythm danger) with opioid interaction risks, creating enough concrete evidence that editors will green-light the investigation.
→ Major news investigations will put ibogaine cardiac deaths into public view, likely triggering political backlash.
Resolves: 2026-08-01 · USA
CULTURE
the precise call ▾
A major investigative piece linking ibogaine cardiac deaths specifically to veteran treatment programs will publish in a top-tier outlet before August 2026.. Today's QT prolongation and ventricular arrhythmia paper plus opioid risk paper gives any investigative journalist the scientific hook. Aaron Rodgers coverage means editors are already primed for ibogaine stories.
74%
Compass stock outperforms MindMed on psilocybin depression data
Compass Pathways' stock will perform better than MindMed's stock (by at least 15% over 6 months) because Compass just published strong depression trial results, while MindMed has weaker clinical data. Institutional money managers follow randomized controlled trial results, not hype—and Compass has cleaner evidence in a validated indication (depression).
→ Real clinical trial wins matter more to investors than market excitement—Compass' depression data beats MindMed's broader promises.
Resolves: 2026-11-18 · Global
MARKET
the precise call ▾
CMPS will outperform MMED by at least 15% on a 6-month basis as psilocybin depression RCT data is absorbed by institutional allocators.. Today's depression RCT directly validates Compass lead indication. MMED's 3.7% gain today is retail momentum — institutional money follows randomized controlled trial data, not hype. CMPS has cleaner regulatory story.